PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Targets Chronic Disease, Preventive Healthcare Market
- Global preventive healthcare technologies and services market expected to reach $432 billion by 2024
- Centers for Disease Control (CDC) states that seven out of 10 U.S. deaths are caused by chronic diseases such as diabetes, with global cost of treating diabetes reaching $776 billion within two decades
- World Health Organization recommended in December 2017 that cannabidiol (CBD) should not be scheduled as a controlled substance, citing its potential as a beneficial pharmaceutical
- PreveCeutical’s CBD-based Sol-gel delivery platform offers ease of application, better bioavailability and controlled cannabidiol release
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. In an exclusive interview with NetworkNewsAudio, PreveCeutical Chairman, CEO and President Stephen Van Deventer shared highlights of the company’s business model, products and R&D programs designed to provide next-generation preventative therapies (http://nnw.fm/kZJ7o). Healthcare issues plaguing hundreds of millions of people around the world – namely diabetes, obesity, pain management, neurological disorders and cancers – are at the heart of PreveCeutical’s research program, he said.
A report by Grand View Research states that the global preventive healthcare technologies and services market is expected to reach $432 billion by 2024 (http://nnw.fm/tiS8M). Innovative, advanced technologies and development of preventive measures is seen as a driving force of the market. Underscoring the significance of this space is the Centers for Disease Control’s assertion that seven out of 10 deaths in the U.S. are caused by chronic disease, which includes diabetes, cancer, heart disease and other conditions classified by the medical community as preventable (http://nnw.fm/4RsB9).
PreveCeutical currently has five research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity. The World Health Organization (WHO) states that some 425 million people around the world are living with diabetes, and that number is projected to rise to 629 million by 2045. Treating diabetes is a costly matter, both economically and in terms of physical harm done to the individual. Healthcare expenditures to treat diabetes totaled $727 billion in 2017, according to Statista (http://nnw.fm/7Q6w1).
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of a key protein molecule, bringing it back down to safe, normalized levels, This would in turn help cells to absorb glucose, thus reducing blood sugar levels and preventing the body from storing excessive fat, Chief Research Officer Dr. Harry Parekh noted in a news release. With over five years of multi-disciplinary research, Parekh’s team has collectively generated convincing results in models of this disease using Smart siRNA and a tissue targeted bio-responsive carrier system. The promise and significance of the company’s research and development divisions is detailed in a May 2018 Crystal Equity Research Report (http://nnw.fm/v68Bp).
Another key research program is the company’s Sol-gel platform, a soluble gel infused with cannabinoids and taken via nasal administration. This CBD-based nose-to-brain delivery system is poised to provide relief for a wide range of indications including seizures. As WHO pointed out in its November 2017 report (http://nnw.fm/Y7n1C), “the clinical use of CBD is most advanced in the treatment of epilepsy.” The key advantages of PreveCeutical’s proprietary formulations are many, including elimination of first pass metabolism, potentially improving bioavailability and extending the release time of the therapy (http://nnw.fm/4Kh12).
PreveCeutical’s vision is simply stated: To be a leader in the preventive health sciences, bringing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Global preventive healthcare technologies and services market expected to reach $432 billion by 2024
- Centers for Disease Control (CDC) states that seven out of 10 U.S. deaths are caused by chronic diseases such as diabetes, with global cost of treating diabetes reaching $776 billion within two decades
- World Health Organization recommended in December 2017 that cannabidiol (CBD) should not be scheduled as a controlled substance, citing its potential as a beneficial pharmaceutical
- PreveCeutical’s CBD-based Sol-gel delivery platform offers ease of application, better bioavailability and controlled cannabidiol release
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. In an exclusive interview with NetworkNewsAudio, PreveCeutical Chairman, CEO and President Stephen Van Deventer shared highlights of the company’s business model, products and R&D programs designed to provide next-generation preventative therapies (http://nnw.fm/kZJ7o). Healthcare issues plaguing hundreds of millions of people around the world – namely diabetes, obesity, pain management, neurological disorders and cancers – are at the heart of PreveCeutical’s research program, he said.
A report by Grand View Research states that the global preventive healthcare technologies and services market is expected to reach $432 billion by 2024 (http://nnw.fm/tiS8M). Innovative, advanced technologies and development of preventive measures is seen as a driving force of the market. Underscoring the significance of this space is the Centers for Disease Control’s assertion that seven out of 10 deaths in the U.S. are caused by chronic disease, which includes diabetes, cancer, heart disease and other conditions classified by the medical community as preventable (http://nnw.fm/4RsB9).
PreveCeutical currently has five research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity. The World Health Organization (WHO) states that some 425 million people around the world are living with diabetes, and that number is projected to rise to 629 million by 2045. Treating diabetes is a costly matter, both economically and in terms of physical harm done to the individual. Healthcare expenditures to treat diabetes totaled $727 billion in 2017, according to Statista (http://nnw.fm/7Q6w1).
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of a key protein molecule, bringing it back down to safe, normalized levels, This would in turn help cells to absorb glucose, thus reducing blood sugar levels and preventing the body from storing excessive fat, Chief Research Officer Dr. Harry Parekh noted in a news release. With over five years of multi-disciplinary research, Parekh’s team has collectively generated convincing results in models of this disease using Smart siRNA and a tissue targeted bio-responsive carrier system. The promise and significance of the company’s research and development divisions is detailed in a May 2018 Crystal Equity Research Report (http://nnw.fm/v68Bp).
Another key research program is the company’s Sol-gel platform, a soluble gel infused with cannabinoids and taken via nasal administration. This CBD-based nose-to-brain delivery system is poised to provide relief for a wide range of indications including seizures. As WHO pointed out in its November 2017 report (http://nnw.fm/Y7n1C), “the clinical use of CBD is most advanced in the treatment of epilepsy.” The key advantages of PreveCeutical’s proprietary formulations are many, including elimination of first pass metabolism, potentially improving bioavailability and extending the release time of the therapy (http://nnw.fm/4Kh12).
PreveCeutical’s vision is simply stated: To be a leader in the preventive health sciences, bringing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
